Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

BACKGROUND. Vascular endothelial growth factor and platelet-derived growth factor signaling in the tumor microenvironment appear to cooperate in promoting tumor angiogenesis. PATIENTS AND METHODS. We conducted a phase I trial combining bevacizumab (i.v. every 2 weeks) and imatinib (oral daily). Once...

詳細記述

保存先:
書誌詳細
出版年:Oncologist
主要な著者: Flaherty, Keith T., Hamilton, Betty K., Rosen, Mark A., Amaravadi, Ravi K., Schuchter, Lynn M., Gallagher, Maryann, Chen, Helen, Sehgal, Chandra, O’Dwyer, Peter J.
フォーマット: Artigo
言語:Inglês
出版事項: AlphaMed Press 2015
主題:
Melanoma and Cutaneous Malignancies
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4524755/
https://ncbi.nlm.nih.gov/pubmed/26084808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0108
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料